Guidance Breakdown: FDA Proposes Pulling Back on Premarket Requirements for NIOSH-Approved Respirators
A quick breakdown of the new draft guidance on compliance policy for certain NIOSH-approved air-purifying respirators used in healthcare settings.
This guidance breakdown is available in full to paid subscribers. Only paid subscribers get regular full access to our guidance breakdowns and other analyses. If you’re not already a paid subscriber, you can upgrade here.
On April 20, the FDA issued a draft guidance titled Compliance Policy Regarding Premarket and Other Requirements for Certain NIOSH Approved Air-Purifying Respirators. The comment period runs 60 days from the Federal Register notice.
Since we work on so many 510(k)s and have partnered with several firms that have brought products in this category to market, we wanted to quickly break down this draft guidance.
Long story short: the FDA is proposing to deprioritize enforcement of most FDA-specific requirements — registration, listing, 510(k), labeling, MDR, UDI — for NIOSH-approved respirators used in healthcare settings for medical purposes. The rationale is that NIOSH’s own approval and oversight program already covers enough ground that layering the FDA’s full device regulatory framework on top adds burden without a corresponding safety benefit.
Here's what's in it and what it means.
What devices does this cover?
The guidance applies to three categories of NIOSH-approved respirators when used for medical purposes:
Surgical N95s and N95 FFRs classified under 21 CFR 878.4040 (product code MSH). These have been Class II devices since 1988. In 2017, the FDA and NIOSH signed an MOU, and in May 2018, the FDA exempted certain surgical N95S and N95 FFRs from 510(k) requirements, subject to conditions.
Other NIOSH-approved, non-surgical respirators. This includes powered air-purifying respirators (PAPRs), non-powered air-purifying particulate FFRs (N95, N99, etc.), and reusable elastomeric half-mask and full-facepiece respirators. The FDA considers these to be post-amendment devices, meaning they’re automatically Class III because they weren’t on the market before the 1976 Medical Device Amendments. They don’t have FDA product codes yet and haven’t been formally classified.
FFRs for use by the general public in public health medical emergencies classified under 21 CFR 880.6260 (product code NZJ). These were classified as Class II in 2007, with a special control requiring NIOSH certification at N95 filtration efficiency or above.
What’s excluded?
The guidance does not cover N95 respirators with antimicrobial or antiviral agents (product codes ORW and ONT). It also excludes any product that makes claims about disease-specific efficacy, infection prevention, viral or bacterial filtration, antimicrobial function, hypoallergenicity, or surgical smoke filtration.
Products with antimicrobial coatings, drug delivery systems, nanoscale technologies, combination products, or emerging tech like germicidal UV are also outside scope. Those products would still need both NIOSH approval and an FDA premarket submission.
What FDA requirements would be deprioritized?
Under this compliance policy, the FDA says it would not prioritize enforcement of:
Registration and listing (21 CFR Part 807)
510(k) premarket notification
Labeling requirements (21 CFR Part 801)
Most of the Quality Management System regulation (21 CFR Part 820), except recordkeeping and complaint handling
Medical Device Reporting / MDRs (21 CFR Part 803)
Unique Device Identification / UDI (21 CFR Parts 830 and 801 Subpart B)
Reports of Corrections and Removals (21 CFR Part 806)
Any special controls not related to NIOSH approval
That’s a lot! Basically, everything in the FDA’s device regulatory toolkit other than recordkeeping and complaints.
What’s still required?
Manufacturers within scope are still expected to comply with recordkeeping and complaint handling requirements under 21 CFR 820.35.
Note: the QMS regulation was amended in February 2024, with the final rule taking effect February 2, 2026. The old recordkeeping and complaint file requirements at 820.180 and 820.198 have moved to 820.35.
The FDA wants to preserve its ability to review complaint records for postmarket surveillance if safety concerns come up. The idea is that manufacturers should still be tracking whether their products meet specifications and responding to complaints, even if most other FDA requirements are on hold.
And of course, NIOSH approval under 42 CFR Part 84 remains fully in effect. (That’s the entire foundation of this compliance policy.)
Why is the FDA doing this?
Two reasons, according to the guidance.
First, NIOSH’s existing oversight is extensive. NIOSH approval requires initial site qualification, product performance testing, quality control plans, respirator label design review, and ongoing conformity assessment. NIOSH issues certificates of approval after examining, inspecting, and testing each respirator. Post-approval, NIOSH conducts product audits and site audits roughly every two years. NIOSH can revoke approvals for cause (for example, if a manufacturer fails to maintain quality control).
Second, the FDA’s own postmarket data doesn’t show a safety problem. The FDA reviewed MDRs for these devices from January 2020 through December 2024 and found no safety signal. During the same period, there were only two voluntary recalls of FFRs, neither of which involved reports of patient harm. (One was a lot-specific filtration efficiency failure on a surgical N95; the other involved 528 PAPRs with potentially mis-assembled headband rivets.)
The guidance also references the “least burdensome” framework — the FDA’s longstanding policy of not imposing regulatory requirements beyond what’s needed to provide reasonable assurance of safety and effectiveness.
The healthcare use question
There’s an important thread running through this document about intended use. The FDA considers respirators used to prevent wearer exposure to pathogenic biological airborne particulates to be devices intended for a medical purpose.
The guidance goes into some detail about why: healthcare settings present distinct respiratory risks from procedures like intubation, aerosolized drug delivery, and work with bone saws, centrifuges, and blenders, plus the baseline risk of caring for patients with respiratory illness.
This isn’t new. The FDA made the same determination in March 2020 when it issued an EUA for NIOSH-approved FFRs in healthcare settings during COVID-19. But the guidance reinforces the point: these are medical devices under the FD&C Act, and the FDA is choosing to exercise enforcement discretion, not saying they’re unregulated.
What about the COVID-era EUAs?
The guidance provides some useful history here. The FDA issued the first respirator EUA on March 2, 2020, authorizing NIOSH-approved FFRs for use by healthcare personnel.
That EUA was amended several times, most recently on July 12, 2021. The COVID public health emergency expired May 11, 2023, but healthcare personnel kept using these respirators. This guidance is essentially the FDA establishing a durable policy framework for a practice that’s been in place for years, and predates COVID, dating back to tuberculosis protocols in the 1990s.
This is a draft guidance. It’s nonbinding. It doesn’t create enforceable obligations. The comment period is the time to weigh in.
And even if finalized, FDA explicitly reserves the right to enforce any FD&C Act requirement at any time. A compliance policy is not an exemption — it’s a statement of current enforcement priorities. FDA can change course for safety reasons or if circumstances shift.
Bottom line
The FDA is proposing to let NIOSH bear most of the regulatory burden for these respirators, rather than duplicating oversight through its own device framework. For manufacturers of NIOSH-approved respirators that are already going through NIOSH’s approval and surveillance process, this would remove a layer of FDA-specific paperwork — registration, listing, 510(k), MDR, UDI, and most QMS requirements — while keeping complaint handling and recordkeeping in place.
If you manufacture or distribute NIOSH-approved respirators for healthcare use, this is worth reading in full and may warrant comment. If you’re on the quality or regulatory side of a healthcare system that uses these products, the practical impact is minimal — you’ll keep sourcing NIOSH-approved respirators the same way you already do. The changes are upstream, at the manufacturer level.
Also, the standard caveats of any draft apply. It’s nonbinding. It doesn’t create enforceable obligations. The comment period is the time to weigh in.
And even if finalized, FDA explicitly reserves the right to enforce any FD&C Act requirement at any time. A compliance policy is not an exemption. It’s a statement of current enforcement priorities. The FDA can change course for safety reasons or if circumstances shift.
Comments go to regulations.gov. Contact PPE@fda.hhs.gov or 1-888-INFO-FDA with questions. Read the full guidance here.
Who is The FDA Group?
The FDA Group helps life science organizations rapidly access the industry's best consultants, contractors, and candidates. Our resources assist in every stage of the product lifecycle, from clinical development to commercialization, with a focus on Quality Assurance, Regulatory Affairs, and Clinical Operations.
Learn more about our brand new AI-powered compliance tool, AICA.
With thousands of resources worldwide, hundreds of whom are former FDA, we meet your precise resourcing needs through a fast, convenient talent selection process supported by a Total Quality Guarantee. Learn more and schedule a call with us to see if we’re a fit to help you access specialized professionals and execute your projects on time and on budget.
The FDA Group's Insider Newsletter is a reader-supported publication. To receive new posts and support our work, consider becoming a paid subscriber.